Osimertinib and Rifampicin (Rifcap 300 mg Kapsül): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong CYP3A induction can lower osimertinib exposure.
Clinical significance and safety
rifampicin in Rifcap 300 mg Kapsül can increase CYP3A-mediated metabolism and reduce osimertinib exposure, risking reduced cancer-treatment effectiveness. The osimertinib label recommends avoiding strong inducers when possible; any unavoidable combination needs the oncology team’s management. Do not change either treatment independently.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.